TransCode Therapeutics Investor Relations Material
Latest events
AGM 2025
TransCode Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from TransCode Therapeutics Inc
Access all reports
TransCode Therapeutics Inc. is a U.S.-based biotechnology company focused on developing RNA-targeted therapies for treating cancer. The company uses its proprietary TTX platform to design and deliver RNA-based therapeutics aimed at addressing previously undruggable cancer targets. TransCode’s research primarily involves preclinical and clinical development of treatments for metastatic and solid tumors, aiming to improve precision and efficacy in cancer treatment. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
RNAZ
Country
🇺🇸 United States